4th Quarter - Report — PHARMACEUTICAL CARE MANAGEMENT ASSOCIAT… for PHARMACEUTICAL CARE MANAGEMENT ASSOCIAT… (2009)

Firm

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Client

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Income

—

Expenses

$456,677

Expense method

C: businesses, Internal Revenue Code section 162(e)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Establishing a regulatory approval pathway for biogeneric drugs - HR 1427/S726 Promoting Innovation and Access to Life Saving Medicine Act and HR 1548 Pathway for Biosimilars Act Items related to the application of drug benefits to public plans and health exchange, include PBM disclosure in HR 3200, S1679 America's Health Future Act, HR 3962, HR3950 Patient Protection and Affordable Care Act.

Lobbyist	Covered position, as disclosed
KRISTIN A BASS	—
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—
JERRY STEFFL	—

Contacted: SENATE; Executive Office of the President (EOP); Medicare Payment Advisory Commission (MedPAC); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3200 (111th), H.R. 3950 (111th), H.R. 3962 (111th), H.R. 1548 (111th), H.R. 1427 (111th)

Medicare/Medicaid MMM

Issues related to Medicare/Medicaid drug coverage including pharmacy payments (average manufacturer price), reimbursements, competition and plan administration, electronic prescribing, chronic care, PBM disclosure. Health reform proposals impacting prescription drug coverage including formulary requirements, generic drug co-payments, direct negotiation, Medicaid rebate changes, applying Medicaid rebates in Medicare, closure of Part D coverage gap, retiree drug subsidy, funding/revenues for Health Care Reform, HR 3200, S1679 America's Health Future Act, HR 3962, HR3950 Patient Protection and Affordable Care Act.

Lobbyist	Covered position, as disclosed
KRISTIN A BASS	—
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—
JERRY STEFFL	—

Contacted: Executive Office of the President (EOP); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 3200 (111th), H.R. 3950 (111th), H.R. 3962 (111th)

Pharmacy PHA

HR 1204 - community Pharmacy Fairness Act; Electronic Prescribing; Mail Order and Pharmacy Chronic Care Management HR 1705, S369 relating to settlement payments between brand and generic manufacturers; Issues related to oversight of pharmacy benefits for federal emloyee health benefits program; Items related to the application of drug benefits to public plans and health exchange, including PBM disclosure in HR 3200, S1679 America's Health Future Act, Issues related to generic dispensing and study of impact of state "carve-out" laws on generic utilization, HR4199 Patients Health and Real Medication Access Cost Savings Act

Lobbyist	Covered position, as disclosed
KRISTIN A BASS	—
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—
JERRY STEFFL	—

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP)

Bills named: H.R. 1204 (111th), H.R. 4199 (111th), H.R. 1705 (111th), H.R. 3200 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.